In a move that has left many in the healthcare industry scratching their heads, pharmaceutical giant Johnson & Johnson has filed a patent for a cardio workout program specifically designed to help cancer patients recover from treatment. Dubbed "Oncology in Motion," the program combines traditional exercise routines with cutting-edge technology to help oncology patients regain their strength and mobility after undergoing chemotherapy or radiation therapy. By targeting the patent-cliff phenomenon, where high-priced medications lose their market exclusivity and become cheaper generic alternatives, J&J may be looking to create a lucrative new revenue stream. But what does this mean for patients, and how will it impact the future of cancer treatment?
All about oncology? A cardio workout? Patent-cliff avoidance? American dreaming?
